Clinical trials: in United Arab Emirates
Diabetes Mellitus, Type 2
Lantus Versus NPH: Comparison in Insulin Naive People Not Adequately Controlled With at Least One Oral Anti Diabetics (OAD) Treatment
Primary Objective: To demonstrate the superiority of insulin glargine over insulin NPH (Neutral Protamin Hagedornon) the change in HbA1c from baseline to the end of the treatment period.
- Trial name
- LANCELOT (NCT00949442)
- Testing
- Insulin Glargine (HOE901) [Lantus], Glimepiride, human insulin [NPH]
- Where
- 87 sites in Brazil, Czechia and 15 more
- Volunteers
- 708 people
- Sponsor
- Sanofi
Hypertension
Treatment of Hypertension With Adalat® in Combination With Other Drugs
To investigate the therapeutic effectiveness of long acting nifedipine containing combination therapy in the treatment of hypertensive patients.
- Trial name
- NCT01118286
- Testing
- Nifedipine (Adalat, BAYA1040)
- Where
- 11 sites in Bahrain, Egypt and 9 more
- Volunteers
- 4,497 people
- Sponsor
- Bayer
Multiple Sclerosis
Physical Activity and Fatigue in Early Multiple Sclerosis (MS)
The purpose of this observational study is to obtain a survey on physical activity in patients who for the first time have experienced symptoms which indicate a high risk for developing multiple sclerosis (MS) and in patients…
- Trial name
- BEGIN (NCT00882453)
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- 33 sites in Australia, Austria and 31 more
- Volunteers
- 1,739 people
- Sponsor
- Bayer
Contraception
Effects of Counseling on the Continuation Rates and Compliance for Newly Prescribed Oral Contraceptives (Yasmin® or Any Other Oral Contraceptives (OC)
This study is a prospective, company-sponsored, non-interventional cohort study of up to 5000 patients in European countries and countries in Middle East who are newly prescribed any available OC.
- Trial name
- NCT00905684
- Testing
- EE30/DRSP (Yasmin, BAY86-5131), Any other OC
- Where
- 13 sites in Albania, Bahrain and 11 more
- Volunteers
- 5,446 people
- Sponsor
- Bayer
Hypogonadism
ESPRIT Study in Hypogonadal Men
Observational study with AndroGel®, Testosterone 1% gel therapy (ESPRIT) in hypogonadal men in the community over 6 months.
- Trial name
- NCT01143818
- Testing
- AndroGel (testosterone gel) 1%
- Where
- 331 sites in Canada, Croatia and 7 more
- Volunteers
- 1,053 people
- Sponsor
- Abbott
Hypercholesterolemia
Centralized Pan-Middle East Survey on the Under-treatment of Hypercholesterolemia, Sub-study for the Gulf States
The purpose of the study is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III guidelines, overall and by country…
- Trial name
- CEPHEUS (NCT01031277)
- Where
- United Arab Emirates
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Hypertension
Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Irbesartan 150 mg Monotherapy
Primary Objective: To demonstrate that the antihypertensive efficacy of the fixed combination irbesartan/amlodipine 300/5 mg is superior to that of irbesartan 300 mg monotherapy in lowering systolic blood pressure (SBP) as…
- Trial name
- I-ADD (NCT00957554)
- Testing
- irbesartan/amlodipine, irbesartan
- Where
- 38 sites in Brazil, Colombia and 6 more
- Volunteers
- 435 people
- Sponsor
- Sanofi
Smoking Cessation
Assessment of Safety and Efficacy of Varenicline in Patients That Wish to Stop Smoking
The primary objective of this protocol is to evaluate 12 weeks of treatment of varenicline compared to placebo for smoking cessation.
- Trial name
- NCT00594204
- Testing
- varenicline tartrate (CP-526, 555-18)
- Where
- 42 sites in Brazil, Colombia and 9 more
- Volunteers
- 593 people
- Sponsor
- Pfizer
Hypertension
ACTUAL: Efficacy and Safety of Irbesartan/Hydrochlorothiazide Combination
To compare the antihypertensive efficacy of the combination irbesartan/hydrochlorothiazide (HCTZ) using either a usual or an active elective titration regimen.
- Trial name
- ACTUAL (NCT00708344)
- Testing
- Irbesartan - Hydrochlorothiazide
- Where
- 16 sites in Algeria, Argentina and 14 more
- Volunteers
- 832 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1
Gulf, Lantus, Apidra Evaluation in Type 1 Diabetics Study
Primary objective : To evaluate the efficacy (in terms of change in HbA1c readings starting from baseline then after 13 weeks \& at the end of the study which will be after 26 weeks) in subjects with type I diabetes mellitus.
- Trial name
- GLANS (NCT00539448)
- Testing
- insulin glargine, insulin glulisine
- Where
- 4 sites in Bahrain, Kuwait and 2 more
- Volunteers
- 98 people
- Sponsor
- Sanofi
Major Depressive Disorder
Multi-Country Observational Study to Collect the Frequency of Sexual Dysfunction With Antidepressant Treatment, Either With SSRIs or Duals at 8 Weeks and 6 Months
In usual clinical conditions, depressed patients with no sexual dysfunction, after signing their consent for the dissemination of their clinical information will begin their treatment with any SSRI or a Dual antidepressant as per…
- Trial name
- NCT00561509
- Testing
- SSRIs, Dual antidepressants
- Where
- 57 sites in Austria, China and 11 more
- Volunteers
- 1,626 people
- Sponsor
- Eli Lilly and Company